| 2.487 -0.043 (-1.7%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.31 | 1-year : | 3.62 |
| Resists | First : | 2.84 | Second : | 3.09 |
| Pivot price | 2.59 |
|||
| Supports | First : | 2.42 | Second : | 2.01 |
| MAs | MA(5) : | 2.48 |
MA(20) : | 2.65 |
| MA(100) : | 2.94  |
MA(250) : | 3.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 13.6 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 4.55 | Low : | 2.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLRX ] has closed above bottom band by 25.1%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.53 | 2.53 - 2.54 |
| Low: | 2.42 - 2.43 | 2.43 - 2.45 |
| Close: | 2.46 - 2.49 | 2.49 - 2.51 |
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Wed, 16 Sep 2026
BioLineRx Ltd. - American Depositary Shares (Nasdaq:BLRX) Detailed Stock Data - The Chronicle-Journal
Thu, 10 Sep 2026
BioLineRx (BLRX) to share new brain tumor drug data at EANO 2026 - Stock Titan
Wed, 09 Sep 2026
BioLineRx (BLRX) sells warrants to fund R&D push - Stock Titan
Tue, 01 Sep 2026
BLRX: New GLIX1 Data Touts Synergies - Yahoo Finance
Mon, 31 Aug 2026
BioLineRx Releases Q2 2026 Financial Results - AlphaStreet
Mon, 31 Aug 2026
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.11e+006 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.212e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 215.3 % |
| Return on Equity (ttm) | -19.9 % |
| Qtrly Rev. Growth | 1.39e+006 % |
| Gross Profit (p.s.) | -4.79 |
| Sales Per Share | -80.11 |
| EBITDA (p.s.) | 1.6087e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.57 |
| Dividend | 0 |
| Forward Dividend | 134580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|